Following the excitement of liquid biopsies at the JP Morgan Health Conference, we were really excited to bring the eagerly anticipated 8th Liquid Biopsy for Precision Oncology Summit to San Diego last month month to delve into critical challenges including biomarker selection, clinical validation, commercialization, reimbursement, and regulation to bring personalized medicine to patients faster. New insights on urine assay technologies, using cell-free RNA, ctDNA, MRD and protein conformational biomarkers to detect disease earlier and better define patient populations for improved outcomes were delivered. Covering the full end-to-end of development from utilizing liquid biopsies for biomarker discovery, to clinical implementation to commercialisation and market access, this event provided a great opportunity to hear from industry leading experts and helped attendees stay ahead of the curve.

You could have joined 250+ peers from drug developers, diagnostics providers, payers and regulatory experts at the largest industry gathering of liquid biopsy experts for an exclusive opportunity of knowledge sharing and networking with the shared objective of developing better precision therapeutics for patients with cancer and beyond.